Tianjin Lisheng Pharma, Tianjin Development Holdings subsidiary, posts H1 net profit RMB 80.08 million

• Tianjin Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings, posted a sharp profit drop in H1 2026.
• Net profit fell to RMB 80.08 million from RMB 345.34 million; net profit attributable to owners slid to RMB 78.33 million from RMB 342.92 million.
• Operating profit declined to RMB 94.9 million from RMB 413.98 million; operating income eased to RMB 641.63 million from RMB 731.51 million.
• Investment income dropped to RMB 9.52 million from RMB 315.67 million.
• Total assets stood at RMB 5.35 billion at June 30, 2026, down from RMB 5.58 billion at Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Development Holdings Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12293424), on August 20, 2026, and is solely responsible for the information contained therein.